Tonight Cramer said tonight on his MAD MONEY show on CNBC there is no reason to wait for the J.P.Morgan Biotech conference, because he already has the stocks to play. Thermo Fisher (TMO) presents…
Tonight Cramer said tonight on his MAD MONEY show on CNBC there is no reason to wait for the J.P.Morgan Biotech conference, because he already has the stocks to play. This makes for many…
Osiris Therapeutics (OSIR) was notified that its PROCHYMAL received FDA ‘Fast Track’designation, expediting thedevelopment of the stem cell treatment for Crohn’s Disease that fails to respond to standard therapies. This takes it to Phase…
From BioHealth Investor The following list represents the top ten medical stocks ranked according to Earnings Per Share and Relative Strength by Investor’s Business Daily (1/06/06) scores out of 100 (last week’s rank, change…
From BioHealth Investor by H.S. AyoubBioHealth Investor.com Biotechnology as a business arguably began with the birth of Genentech (DNA) 30 years ago in 1976. The company had a successful IPO four years later in…
Tonight Cramer continued his quest of delivering his favorite TOP 3 SPECULATIVE STOCKS FOR 2007. Cramer started off with his #3 pick, or the second runner up for the speculative stocks. Savient Pharma (SVNT)…
From BioHealth Investor Bioject Medical Technologies Inc (BJCT) announced early Thursday that the National Institutues of Health (NIH) has initiated its DNA vaccine study to prevent the H5N1 flu virus using the company’s needl-free…
From BioHealth Investor by H.S. AyoubBioHealth Investor Stem cell stocks gained big time on Thursday as the new U.S. congress was set to take helm. The new Domocratic agenda promises to ease restrictions on…
Stocks: (PFE)(MRK)(TEVA) Conventional wisdom has been that generic drug companies are going to put Big Pharma out of business. As major drugs come "off patent", the generic guys snap them up and sell them…
Pfizer is raising prices on its drugs an average of about 5% going into 2007. Lipitor, the world’s top-selling drug, will see of price increase of at least that much. After the failure its…
From BioHealth I read a very well written article penned recently by Nature staff reporter Erika Check for Wired Magazine. Ms.Check profiles a popular nationalist in India by the name of Khwaja Abdul Hamied,…
From BioHealth Investor It seems like Vertex Pharmaceuticals (VRTX) is the subject of the majority of my articles (link one, two, three to past articles) and for good reasons. VRTX is looking to become…